These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 34522442)

  • 1. Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.
    Kim JY; Bae S; Park S; Kwon JS; Lim SY; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Heo J; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Aug; 21(4):e29. PubMed ID: 34522442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
    Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
    J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination.
    Lim SY; Kim JY; Park S; Kwon JS; Park JY; Cha HH; Suh MH; Lee HJ; Lim JS; Bae S; Jung J; Lee N; Kim K; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Dec; 21(6):e41. PubMed ID: 35036028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers.
    Benning L; Töllner M; Hidmark A; Schaier M; Nusshag C; Kälble F; Reichel P; Buylaert M; Grenz J; Ponath G; Klein K; Zeier M; Süsal C; Schnitzler P; Morath C; Speer C
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34451982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients.
    Lim SY; Yoon YI; Kim JY; Tak E; Song GW; Kim SH; Lee SG
    Immune Netw; 2022 Jun; 22(3):e24. PubMed ID: 35799703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
    Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
    Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
    Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    Front Immunol; 2022; 13():975363. PubMed ID: 36119092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of adaptive immune responses in healthcare workers who received a Coronavirus disease 2019 vaccine booster dose.
    Klinmalai C; Srisala S; Sahakijpicharn T; Apiwattanakul N
    Health Sci Rep; 2024 Jul; 7(7):e2250. PubMed ID: 39015422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
    Lim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim SH; Kim CK; Kim T; Choo EJ; Moon JE; Yun J; Park SK
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations.
    Lee TH; Nam M; Seo JD; Kim H; Kim HR; Hur M; Yun YM; Moon HW
    Ann Lab Med; 2023 May; 43(3):290-294. PubMed ID: 36544341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
    Michiels Y; Houhou-Fidouh N; Collin G; Berger J; Kohli E
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
    Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination.
    Bauswein M; Peterhoff D; Plentz A; Hiergeist A; Wagner R; Gessner A; Salzberger B; Schmidt B; Bauernfeind S
    iScience; 2022 Feb; 25(2):103694. PubMed ID: 35013723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
    Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.